Cardiol Therapeutics Inc. (CRDL.TO)
| Previous Close | 3.2800 |
| Open | 3.4000 |
| Bid | 2.9800 x 0 |
| Ask | 3.0000 x 0 |
| Day's Range | 2.9600 - 3.4600 |
| 52 Week Range | 0.9100 - 4.2600 |
| Volume | |
| Avg. Volume | 146,182 |
| Market Cap | 204.925M |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4700 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.30 |
- Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Added another feather to its cap last week with the announcement of its Phase II MAvERIC-Pilot study ...
- ACCESSWIRE
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
NAPLES, FL / ACCESSWIRE / June 17, 2024 / In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ:CRDL)(TSX:CRDL) added another feather to its cap last week with the announcement of its Phase II MAvERIC-Pilot ...
NewsfileCardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have continued into the extension phase of the studyToronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and a
